Retatrutide and Tirzepatide: Retatrutide and Tirzepatide are newer additions to the GLP-1 analogue family and are currently under investigation in clinical trials for obesity treatment
Wegovy may be recommended for adult patients who are: Medically overweight or obese (BMI of 30 or higher), or Have a BMI of 27 or higher and at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol
[DOI] [PMC free article] [PubMed] [Google Scholar] 191.Liao B., Zhao Y., Wang D., Zhang X., Hao X., Hu M
Roseanne Schnell (RD) Our expert coaches and nutritionists have created online resources to help you make lasting lifestyle changes
Clinical studies show maximal reduction in ALT levels (a marker of liver damage) was achieved approximately 28-30 weeks after starting treatment 20
Sublingual nausea tends to be milder than injection-related nausea because the medication absorbs more gradually